Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RLS-0071 in Steroid-Refractory Acute Graft-versus-Host Disease
2024-510582-42-00Phase 2Withdrawn
- Sponsor
- ReAlta Life Sciences
- Start
- Jul 2024
- Modality
- Peptides
- Countries
- 3
01
Overview
Phase 2, open-label trial of pegtarazimod in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by ReAlta Life Sciences. Primary endpoints: Safety and tolerability of RLS-0071 in the treatment of acute graft-versus-host disease and Overall response rate (ORR) at Day 28. Planned start Jul 2024; status: withdrawn.
02
Drugs
pegtarazimod
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on 2024-510582-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510582-42-00.